Abstract:Highlights • Radiotherapy promotes the binding of CDK2 and TRIM32, thus leading to increased CDK2-dependent phosphorylation of TRIM32 at serines 328 and 339. • Cis-trans isomerization of TRIM32 recruit PIN1, which resulting in importin α3 binding to TRIM32 and contributing to its nuclear translocation. • Nuclear TRIM32 inhibits TC45-dephosphorylated STAT3, Leading to increased transcription of STAT3 and radioresistance in triple-negative breast cancer (TNBC). • Regulating the CDK2/TRIM32/STAT3 pathway is a promising strategy for reducing radioresistance in TNBC, which is important for TNBC therapy. Introduction Despite radiotherapy being one of the major treatments for triple-negative breast cancer (TNBC), new molecular targets for its treatment are still required due to radioresistance. CDK2 plays a critical role in TNBC. However, the mechanism by which CDK2 promotes TNBC radioresistance remains to be clearly elucidated. Objectives We aimed to elucidate the relationship between CDK2 and TRIM32 and the regulation mechanism in TNBC. Methods We performed immunohistochemical staining to detect nuclear TRIM32, CDK2 and STAT3 on TNBC tissues. Western blot assays and PCR were used to detect the protein and mRNA level changes. CRISPR/Cas9 used to knock out CDK2. shRNA-knockdown and transfection assays also used to knock out target genes. GST pull-down analysis, immunoprecipitation (IP) assay and in vitro isomerization analysis also used. Tumorigenesis studies also used to verify the results in vitro. Results Herein, tripartite motif-containing protein 32 (TRIM32) is revealed as a substrate of CDK2. Radiotherapy promotes the binding of CDK2 and TRIM32, thus leading to increased CDK2-dependent phosphorylation of TRIM32 at serines 328 and 339. This causes the recruitment of PIN1, involved in cis-trans isomerization of TRIM32, resulting in importin α3 binding to TRIM32 and contributing to its nuclear translocation. Nuclear TRIM32 inhibits TC45-dephosphorylated STAT3, Leading to increased transcription of STAT3 and radioresistance in TNBC. These results were validated by clinical prognosis confirmed by the correlative expressions of the critical components of the CDK2/TRIM32/STAT3 signaling pathway. Conclusions Our findings demonstrate that regulating the CDK2/TRIM32/STAT3 pathway is a promising strategy for reducing radioresistance in TNBC. Graphical abstract Download : Download high-res image (170KB) Download : Download full-size image

Silencing of XRCC4 increases radiosensitivity of triple-negative breast cancer cells.

Silencing of CXCR4 Sensitizes Triple-Negative Breast Cancer Cells to Cisplatin

Downregulation of TMPRSS4 Enhances Triple-Negative Breast Cancer Cell Radiosensitivity Through Cell Cycle and Cell Apoptosis Process Impairment.

Building Radiation-Resistant Model in Triple-Negative Breast Cancer to Screen Radioresistance-Related Molecular Markers

shRNA-mediated XRCC2 gene knockdown efficiently sensitizes colon tumor cells to X-ray irradiation in vitro and in vivo.

Data from ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer

Estrogen Receptor Mediates the Radiosensitivity of Triple-Negative Breast Cancer Cells

Inhibition of PC4 Radiosensitizes Non‐small Cell Lung Cancer by Transcriptionally Suppressing XLF

CXCR6 expression correlates with radiotherapy response and immune context in triple-negative breast cancer-experimental studies

CDK2-activated TRIM32 phosphorylation and nuclear translocation promotes radioresistance in triple-negative breast cancer

MicroRNA-384 radiosensitizes human non-small cell lung cancer by impairing DNA damage response and repair signaling, which is inhibited by NF-κB

Triple‑negative breast cancer cells that survive ionizing radiation exhibit an Axl‑dependent aggressive radioresistant phenotype

[Down Regulation of Multidrug Resistance-Associated Protein 4 Expression by RNA Interference Enhances Radiosensitivity of Colorectal Carcinoma Cell Lines in Vitro].

Radiation Enhances the Efficacy of EGFR-targeted CAR-T Cells Against Triple-Negative Breast Cancer by Activating NF-κB/Icam1 Signaling.

Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide

Targeting DNA damage repair mechanism by using RAD50-silencing siRNA nanoparticles to enhance radiotherapy in triple negative breast cancer

Abstract 3198: Comprehensive Transcriptome Analysis Identifies Integrated Mrna-Lncrna Signature of Triple-Negative Breast Cancer Treated with Radiotherapy

Transcriptome Profiling Reveals Novel Radiosensitivity Predictors by Integrating Molecular Subtype and Radiosensitivity Signature in Triple-Negative Breast Cancer

Xrcc3 is A Promising Target to Improve the Radiotherapy Effect of Esophageal Squamous Cell Carcinoma

Knockdown of PC4 Increases Chemosensitivity of Oxaliplatin in Triple Negative Breast Cancer by Supressing Mtor Pathway

CBX4 contributes to radioresistance by regulating autophagic activity in esophageal squamous cell carcinoma